- ISIN
- US09203E1055
- CUSIP
- 09203E105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 30, 2020
Highlights
- Market Cap
- $92.15M
- Enterprise Value
- $76.16M
- EPS (TTM)
- -$0.76
- Gross Profit (TTM)
- -$152.00K
- EBITDA (TTM)
- -$40.34M
- Year Range
- $1.61 - $4.94
- Target Price
- $8.00
- ROA (TTM)
- -32.51%
- ROE (TTM)
- -41.43%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BDTX Performance Chart
Black Diamond Therapeutics, Inc. (BDTX) is down 33.7% since the beginning of the year. At $2 per share, BDTX is trading 67.4% below its 52-week high of $5. Investors who bought $1,000 worth of BDTX shares 5 years ago would now be looking at an investment worth $131.
Loading charts...
Returns By Period
Black Diamond Therapeutics, Inc. (BDTX) has returned -33.74% so far this year and -30.90% over the past 12 months.
Black Diamond Therapeutics, Inc.
- 1D
- -3.01%
- 1M
- -29.39%
- YTD
- -33.74%
- 6M
- -38.08%
- 1Y
- -30.90%
- 3Y*
- -4.00%
- 5Y*
- -33.44%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
BDTX Monthly Returns History
Based on dividend-adjusted daily data since Jan 30, 2020, BDTX's average daily return is +0.02%, while the average monthly return is +0.04%. At this rate, an investment would double in approximately 144.4 years.
Historically, 45% of months were positive and 55% were negative. The best month was Jun 2023 with a return of +171.5%, while the worst month was May 2021 at -50.8%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 9 months.
On a daily basis, BDTX closed higher 45% of trading days. The best single day was Jun 27, 2023 with a return of +235.9%, while the worst single day was May 20, 2021 at -37.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.47% | -0.80% | -13.77% | 24.41% | -16.23% | -27.48% | -33.74% | ||||||
| 2025 | 22.43% | -23.28% | -22.89% | 9.68% | 29.41% | 12.73% | 7.26% | 3.38% | 37.82% | 2.11% | -1.29% | -36.39% | 13.55% |
| 2024 | 36.65% | 33.98% | -1.46% | 9.86% | -14.18% | -2.51% | 30.69% | 0.16% | -28.69% | -37.01% | -3.28% | -19.25% | -23.84% |
| 2023 | 66.67% | -41.00% | 6.78% | -24.34% | 30.07% | 171.51% | -26.14% | -9.65% | -14.84% | -34.49% | 24.47% | 20.09% | 56.11% |
| 2022 | -21.76% | -24.70% | -11.78% | -12.27% | -30.45% | 45.56% | 42.28% | -8.86% | -47.02% | 36.69% | -8.66% | -14.69% | -66.23% |
| 2021 | -22.71% | 13.04% | -13.36% | 9.81% | -50.75% | -7.09% | -21.58% | 5.65% | -16.24% | -9.46% | -21.67% | -11.17% | -83.37% |
Benchmark Metrics
Black Diamond Therapeutics, Inc. has an annualized alpha of -15.40%, beta of 1.38, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since January 30, 2020.
- This stock participated in 226.96% of S&P 500 Index downside but only 110.18% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -15.40%
- Beta
- 1.38
- R²
- 0.05
- Upside Capture
- 110.18%
- Downside Capture
- 226.96%
Return for Risk
Risk / Return Rank
BDTX ranks 28 for risk / return — below 28% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Black Diamond Therapeutics, Inc. (BDTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BDTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.40 | ||
| Sortino ratioReturn per unit of downside risk | -2.75 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 1.37 | -0.37 |
| Calmar ratioReturn relative to maximum drawdown | -0.46 | 2.78 | -3.25 |
| Martin ratioReturn relative to average drawdown | -0.82 | 12.44 | -13.26 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Black Diamond Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Black Diamond Therapeutics, Inc. was 97.21%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Black Diamond Therapeutics, Inc. drawdown is 96.41%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -97.21%Apr 2025 | 4y 9mo | — | 6y 1dJun 2020 - now |
COVID crash2020 | -53.95%Mar 2020 | 1mo 17d | 1mo 7d | 2mo 24dJan 2020 - Apr 2020 |
2020 correction2020 | -19.84%Jun 2020 | 1mo | 10d | 1mo 10dMay 2020 - Jun 2020 |
2020 correction2020 | -17.80%May 2020 | 3d | 7d | 10dApr 2020 - May 2020 |
Drawdown Indicators
| BDTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.21% | -56.78% | -40.43% |
Max Drawdown (1Y)Largest decline over 1 year | -66.94% | -9.10% | -57.84% |
Max Drawdown (3Y)Largest decline over 3 years | -83.09% | -18.90% | -64.19% |
Max Drawdown (5Y)Largest decline over 5 years | -90.28% | -25.43% | -64.85% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -96.41% | -1.80% | -94.61% |
Average DrawdownAverage peak-to-trough decline | -78.67% | -10.71% | -67.96% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.52% | 2.03% | +35.49% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Black Diamond Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Black Diamond Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BDTX in comparison with other companies in the Biotechnology industry. Currently, BDTX has a P/B value of 0.9. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BDTX
Add Black Diamond Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BDTX